DICE Therapeutics, Inc.
DICE · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | 30.4% | -85.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -4,324.4% | -2,651.8% | -211.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -4,308.6% | -2,752.3% | -224.5% |
| EPS Diluted | -2.07 | -3.91 | -1.02 | -0.56 |
| % Growth | 47.1% | -283.3% | -82.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |